Aravax uses proprietary technology to precisely reset the immune system to tolerate allergens without evoking allergic reactions during treatment.
​
Aravax's lead product for peanut allergy (PVX108) is currently being tested in Phase 2 trials in adolescents and children at clinics in Australia and the United States.
Aravax was founded in May 2015 from intellectual property developed by Alfred Health and Monash University, and investment from the Medical Research Commercialisation Fund (MCRF), managed by Brandon Capital Partners.
​
As part of closing a Series B funding round in January 2024, Aravax welcomed new investors Novartis Venture Fund, Tenmile, Breakthrough Victoria, Uniseed, and UniSuper to support the Phase 2 development of PVX108 and expand the product pipeline.
​
The company is headquartered in Melbourne, Australia.
About Aravax
​
About Food Allergy
​
Food allergy is a rapidly growing problem in countries around the world. About one person in every ten is allergic to one or more foods, and many go on to suffer a serious, potentially life-threatening reaction to those foods which cannot be predicted or prevented. Fatalities are fortunately rare, but food allergy sufferers live in constant fear of an accidental encounter with the food(s) to which they are allergic.
Normally, our immune system does not react to foods when we are exposed to them. However, in people that suffer from food allergy, the immune system recognises certain foods as potentially dangerous which triggers an immune response. This response can lead to a range of symptoms, from mild itchiness, rash, gastrointestinal upset, swelling of the airways and critically low blood pressure through to life-threatening anaphylaxis.